GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hanall Biopharma Co Ltd (XKRX:009420) » Definitions » Capital Expenditure
中文

Hanall Biopharma Co (XKRX:009420) Capital Expenditure

: ₩-9,197.67 Mil (TTM As of Dec. 2023)
View and export this data going back to 1989. Start your Free Trial

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Hanall Biopharma Co's cash flow for capital expenditures for the three months ended in Dec. 2023 was ₩-2,005 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Dec. 2023 was ₩-9,197.67 Mil.


Hanall Biopharma Co Capital Expenditure Historical Data

The historical data trend for Hanall Biopharma Co's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hanall Biopharma Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capital Expenditure
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8,275.83 -7,389.65 -9,002.10 -7,676.96 -9,197.67

Hanall Biopharma Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,324.18 -2,437.34 -1,762.02 -2,993.56 -2,004.75

Hanall Biopharma Co Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-9,197.67 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hanall Biopharma Co (XKRX:009420) Business Description

Traded in Other Exchanges
N/A
Address
12 Bongeunsa-ro 114-gil, Daewoong Building, 3rd Floor, Gangnam-gu, Seoul, KOR
Hanall Biopharma Co Ltd is a part of the healthcare sector. It is one of Korea's leading pharmaceutical companies and is focused on drug delivery, biotherapeutics, and new small molecule discovery. The company's scope comprises of ophthalmology, immunology, cardiovascular treatment and dermatology.

Hanall Biopharma Co (XKRX:009420) Headlines

No Headlines